Yantai Development Zone builds an integrated industrial chain of pharmaceutical R&D and manufacturing to promote the industrialization of new biological drugs

The biopharmaceutical industry is a key emerging industry cultivated in Yantai Development Zone. After nearly 20 years of unremitting cultivation, it has entered a golden period of rapid development. During the "13th Five-Year Plan" period, it maintained a double-digit annual growth rate and was approved as the "National Torch". Biological and New Pharmaceutical Characteristic Industrial Base" helped Yantai's biopharmaceutical industry be selected as one of the first batch of 66 national strategic emerging industrial clusters in the country.

Yantai Development Zone has now formed an industrial chain layout covering the R&D and manufacturing of biological medicines, chemical medicines, modern Chinese medicines, and medical devices, and has become an important engine for driving and leading the development of regional strategic emerging industries in the future.

Yantai Development Zone Biopharmaceutical Industrial Park, coordinating the industrial development positioning, spatial layout and supporting infrastructure, arranges Rongchang Biomedical Park, Dongcheng Biomedical Park, Progi Biomedical Park, New Era Health Industrial Park and other parks in turn. The "Park in the Park" model realizes the interactive combination of large and small parks, dislocation competition, and cluster development, and builds a biomedical industry system with scientific and reasonable layout, clear division of labor, and increasingly complete functions.

126 biomedical companies have gathered in the park, including 4 listed companies, 31 high-tech companies, and 51 nationally registered technology-based small and medium-sized enterprises. A number of Rongchang Pharmaceuticals, Dongcheng Pharmaceuticals, Simcere Biotech, Zhenghai Biotech, Backbone enterprises such as Progi. Dongcheng Pharmaceutical is one of the top 100 chemical drugs in the country, Rongchang Bio is one of the top 100 pharmaceutical innovative companies in China, and Aidekang has become the largest manufacturer of enzyme-linked immune equipment in China.

Among them, Rongchang Biology can be described as the brightest star in the park. In the first half of this year, the company's two world-first and class-leading new biological drugs have been approved for listing. Among them, tytaxel was approved for marketing on March 9, and it is the world's first dual-target innovative drug for the treatment of systemic lupus erythematosus; the first indication of vedicitumumab was approved for marketing on June 8. Become my country's first self-developed antibody-conjugated drug (ADC). At present, the industrialization of the world's leading new biological drugs originally created by Rongchang is fully advancing.

In addition to this star, there are more than 200 nationally approved drugs and 150 medical devices in the Biomedical Industrial Park of the Development Zone. A total of 116 scientific and technological projects at the municipal level and above have been undertaken, including 24 major special projects such as the national "863" plan and the national "Major New Drug Development"; the total number of national Class I new drugs and national Class III medical devices approved and under development has reached 95 . It is domestically leading in antibody drugs, recombinant protein drugs, peptide drugs and other fields. Products such as biofilms, bone repair materials, and new nerve repair materials have a strong competitive advantage in China. "Aidixi" (RC48), which is used to treat diseases such as breast cancer and gastric cancer, is my country's first ADC new drug to enter human clinical trials; "Heat shock protein 90α tumor detection product" for tumor marker detection is listed It is a major national original achievement; Junxiu's first three-category medical device "Acellular Matrix Peripheral Nerve Repair Membrane" product was approved for marketing in 2019. A total of 731 domestic patents and 98 foreign patents have been applied for.